Novozymes A/S CVR number: 10 00 71 27 LEI: 529900T6WNZXD2R3JW38
9M 2021
Stronger performance leads to increased full-year outlook; organic
sales growth at 5-6% and EBIT margin at around 27%.
Organic sales growth of 6% (Q3: 7%) in 9M 2021: Household Care 0% (Q3: 3%); Food, Beverages & Human Health
15% (Q3: 16%); Bioenergy 12% (Q3: 5%); Grain & Tech Processing 12% (Q3: 4%); Agriculture, Animal Health &
Nutrition -3% (Q3: 16%). EBIT margin at 28.8% (Q3: 29.1%). ROIC incl. goodwill at 22.1% (Q3: 21.4%). FCF bef.
acq. at DKK 2.7 billion (Q3: DKK 0.9 billion).
Ester Baiget, President & CEO: "Nine months into the year, our momentum remains strong with double-digit
organic sales growth in three of our five business areas, along with strong earnings. Consequently, we are
upgrading our full-year outlook. We focus on driving our strategy “Unlocking Growth – Powered by Biotech”
forward without compromising the execution and delivery of shorter-term targets. We know there is a growing
demand for our biological and sustainable solutions and key for us is to prioritize among the available
opportunities to maximize return on investment, while always having a clear sustainability mindset in everything
we do. So far, we’re clearly heading in the right direction.”
In summary (9M):
• Double-digit growth in Food, Beverages & Human Health across subareas with supportive market
conditions. Household Care recovered in Q3 but by less than projected mainly due to softer than expected
European performance. The Freshness platform and emerging markets contributed positively and
according to plan.
• Double-digit growth in Bioenergy mainly from a recovering U.S. ethanol production and expansion of
starch-based ethanol production in Latin America. Double-digit growth in Grain & Tech Processing led by
strong demand for ag-processing solutions and solid recovery in textile. Agriculture, Animal Health &
Nutrition as expected with double-digit growth in Q3.
• Strong organic sales growth of 20% in emerging markets; developed markets flat.
• Eight products launched year to date, with four launches in the third quarter, including Pristine® for
Freshness to the broad markets as well as new solutions for agriculture.
• Strong EBIT margin at 28.8% with strong operational leverage and supportive one-offs and despite higher
operating costs, currency headwinds and acquisition effects.
• Free cash flow before acquisitions strong at DKK 2.7 billion and ROIC incl. goodwill was strong at 22.1%.
• Solid balance sheet with NIBD/EBITDA of 0.8x. DKK 1.5bn share buyback program completed on Aug. 27.
• New collaboration with Anuvia Plant Nutrients in the field of bio-nutrients for sustainable agriculture.
2021 outlook raised: Organic sales growth is lifted to the upper end of the previous outlook range to now 5%
to 6%, with sales growth in reported DKK roughly on par with the organic sales growth. The EBIT margin outlook
is increased from previously ~26% to now around 27%. ROIC incl. goodwill and FCF bef. acq. are raised to 20%
to 21% and DKK 2.8 to 3.2 billion respectively.
9M 2021
9M 2020
2021 outlook
October 26
2021 outlook
August 12
Sales performance, organic
%
6
1
5 to 6
4 to 6
EBIT margin
%
28.8
27.0
~27
~26
ROIC, incl. goodwill
%
22.1
19.2
20 to 21
19 to 20
Free cash flow before acquisitions
DKKbn
2.7
2.7
2.8 to 3.2
2.5 to 2.9
October 26, 2021
Interim report for 9M 2021.
Company announcement
no. 47
Novozymes A/S
Krogshoejvej 36
2880 Bagsvaerd
Denmark
Phone: +45 4446 0000
Interim report for 9M 2021. Company announcement No. 47
2/28
Selected key data
9M 2021
9M 2020
Q3 2021
Q3 2020
Sales performance, organic
%
6
1
7
-3
Household Care
%
0
7
3
-1
Food, Beverages & Human Health
%
15
3
16
-5
Bioenergy
%
12
-10
5
-4
Grain & Tech Processing
%
12
1
4
9
Agriculture, Animal Health & Nutrition
%
-3
4
16
-19
Sales
DKKm
11,117
10,566
3,761
3,431
Sales performance, DKK
%
5
-1
10
-7
Gross margin
%
58.2
56.2
57.9
56.1
EBITDA
DKKm
4,273
3,775
1,448
1,209
EBIT
DKKm
3,202
2,856
1,095
894
EBIT margin
%
28.8
27.0
29.1
26.1
Net profit
DKKm
2,522
2,172
843
711
Net profit performance
%
16
-3
19
11
Net investments excl. acquisitions
DKKm
638
593
227
229
Free cash flow before acquisitions
DKKm
2,729
2,716
883
665
NIBD/EBITDA (x)
0.8
0.9
0.8
1.0
ROIC, incl. goodwill
%
22.1
19.2
21.4
18.9
EPS
DKK
9.06
7.73
3.04
2.54
EPS (diluted)
DKK
8.99
7.69
3.01
2.53
Avg. USD/DKK
622
663
631
637
Interim report for 9M 2021. Company announcement No. 47
3/28
Sales by business area
Distribution of sales by business area, 9M 2021
Household Care
Household Care reported a flat organic sales performance for the first nine months of 2021 compared to the
same period last year, while sales in reported DKK declined 3% for the period. The overall performance was
solid, although below expectations in the third quarter, and against a tough comparator following last year's
COVID-19-related sales surge. Emerging markets performed well, with growth mainly driven by increased
enzymatic penetration, while developed markets declined mainly due to softer than expected performance in
Europe in the third quarter.
Third-quarter sales grew by 3%, both organically and in reported DKK year on year. Growth was driven by
emerging markets while developed markets, particularly Europe, declined due to softer than expected end-
market demand and certain private-label customers experiencing difficulties.
Food, Beverages & Human Health
Food, Beverages & Human Health performed well and grew 15% organically in the first nine months of 2021
compared to the same period last year. Sales in reported DKK grew 24%, supported by the two recent Human
Health acquisitions. Growth was broad based, with all subareas growing by or close to double digits organically.
Performance was particularly strong in the health-focused categories such as dairy, plant-based protein and
Human Health. In addition, Beverages performed well, driven by customer raw material optimization, low-
calorie brews and an increased demand following relaxed COVID-19 lockdown measures.
In the third quarter, sales grew 16% organically and 27% in reported DKK year on year. The performance was
broad based and exceeded expectations, with less-than-expected destocking. Food, and particularly baking,
performed especially well, driven by raw material optimization and ingredient replacement. All major regions
grew in the third quarter, with emerging markets outgrowing developed markets. The business benefitted from
high consumer retail spending, continued elevated stock levels, and positive timing effects in Beverages. Human
Health performed very well and according to expectations.
Bioenergy
Bioenergy sales grew 12% organically in the first nine months of the year and by 5% in reported DKK year on
year. The strong performance was driven by a recovery of U.S. ethanol production volumes following last year’s
severe COVID-19-related disruption, and the continued expansion of starch-based ethanol production capacity
in Latin America. Sales of solutions used for biodiesel production grew strongly in the first nine months, although
from a relatively low absolute level.
Third-quarter Bioenergy sales grew 5% on top of a somewhat more normalized baseline following last year’s
severe disruption of North American ethanol production volumes in the second quarter. Sales in reported DKK
32%
24%
17%
15%
12%
Household Care
Food, Beverages & Human Health
Bioenergy
Grain & Tech Processing
Agriculture, Animal Health & Nutrition
Organic performance / Performance in DKK
-3% / -6%
0% / -3%
12% / 9%
15% / 24%
12% / 5%
Total sales 9M y/y
Organic: 6%
DKK: 5%
Household Care 9M y/y
Organic: 0%
DKK: -3%
Food, Beverages & Human Health
9M y/y
Organic: 15%
DKK: 24%
Bioenergy 9M y/y
Organic: 12%
DKK: 5%
Interim report for 9M 2021. Company announcement No. 47
4/28
grew 4% year on year. Sales benefitted from good developments in Latin America and from sales of solutions
for biodiesel production.
Grain & Tech Processing
In the first nine months of 2021, Grain & Tech Processing sales grew 12% organically and 9% in reported DKK
compared to the same period last year. The performance was above expectations, with both Grain and Tech
Processing growing in the double digits. Growth in Grain was driven by strong performance in starch and
vegetable oil processing, while growth in Tech Processing was driven by a recovery in the global textile business
following last year´s severe COVID-19-related disruption.
Grain & Tech Processing sales grew 4% organically and 5% in reported DKK in the third quarter compared to the
same period last year. The performance was better than expected, mainly driven by Grain with less-than-
expected destocking after a very strong second quarter. Tech Processing declined slightly in line with
expectations.
Agriculture, Animal Health & Nutrition
Sales in Agriculture, Animal Health & Nutrition declined 3% organically and 6% in reported DKK in the first nine
months compared to the same period last year. The decline was expected and mainly due to a negative base
effect from last year’s DKK ~60 million one-off related to the former BioAg setup. Animal Health & Nutrition
grew slightly following a demanding year-to-date comparator in Animal Nutrition. Adjusted for the BioAg one-
off, Agriculture, Animal Health & Nutrition organic sales grew slightly compared to the first nine months of last
year.
Third-quarter sales grew 16% organically and 15% in reported DKK year on year. Growth was mainly driven by
a strong performance in Animal Health & Nutrition as last year’s challenging comparator eased in the third
quarter. Agriculture also performed well and grew at close to double digits compared to the third quarter of
last year.
Grain & Tech Processing 9M y/y
Organic: 12%
DKK: 9%
Agriculture, Animal Health &
Nutrition 9M y/y
Organic: -3%
DKK: -6%
Interim report for 9M 2021. Company announcement No. 47
5/28
Sales by geography
Distribution of sales by geography, 9M 2021
Novozymes’ organic sales grew 6% year on year in the first nine months of 2021. Sales in emerging markets
grew 20% while developed markets were flat. The strong performance in emerging markets was broad based
with all five business areas growing organically relative to low single-digit growth comparators from last year.
Sales in developed markets were mixed with Food, Beverages & Human Health, Bioenergy and Grain & Tech
Processing doing well, while Agriculture, Animal Health & Nutrition and Household Care declined. The strong
growth in emerging markets was inflated by a year on year change in ship-to destination for Agriculture, Animal
Health & Nutrition.
In the third quarter, emerging markets grew 25% while developed markets declined 1% organically. All five
business areas delivered solid growth in emerging markets, while Household Care, Grain & Tech Processing and
Agriculture, Animal Health & Nutrition declined in developed markets.
Europe, the Middle East & Africa
Sales grew 2% organically in the first nine months of the year compared to the same period last year. The
performance was mixed with growth in Food, Beverages & Human Health and Bioenergy while Agriculture,
Animal Health & Nutrition, Household Care and Grain & Tech Processing declined.
Third-quarter sales grew 3%, mainly driven by Food, Beverages & Human Health while Grain & Tech Processing
and Household Care declined.
North America
North America grew 2% organically year on year in the first nine months. Bioenergy and Grain & Tech Processing
were the main growth drivers while Household Care and Agriculture, Animal Health & Nutrition declined.
Sales in the third quarter grew 1% year on year with the same performance across business areas as in the first
nine months.
Asia Pacific
Sales grew 12% organically in the first nine months of the year, driven by broad based growth. Food, Beverages
& Human Health, Grain & Tech Processing and Household Care were particularly strong.
Sales in the third quarter grew 11% with all business areas contributing except for Grain & Tech Processing
which was roughly flat.
39%
30%
20%
11%
Europe, the Middle East & Africa
North America
Asia Pacific
Latin America
Europe, the Middle East & Africa
9M y/y
Organic: 2%
DKK: 2%
North America 9M y/y
Organic: 2%
DKK: 1%
Asia Pacific 9M y/y
Organic: 12%
DKK: 10%
31% / 21%
Organic performance / Performance in DKK
2% / 2%
12% / 10%
2% / 1%
Interim report for 9M 2021. Company announcement No. 47
6/28
Latin America
Organic sales in Latin America grew by 31% in the first nine months of the year compared to the same period
last year. The strong performance was broad based and especially strong in Animal Nutrition and in starch-
based ethanol.
In the third quarter, sales in Latin America grew 41%, with strong growth across all business areas.
Latin America 9M y/y
Organic: 31%
DKK: 21%
Interim report for 9M 2021. Company announcement No. 47
7/28
Income statement
Total costs, excluding net other operating income, net financials, share of losses in associates and taxes
amounted to DKK 8,065 million in the first nine months and DKK 2,676 million in the third quarter of 2021. This
was DKK 302 million (4%) and DKK 131 million (5%) higher compared to the respective periods of 2020.
The gross margin ended at 58.2% in the first nine months and at 57.9% in the third quarter of 2021,
corresponding to an increase of 2.0 and 1.8 percentage points respectively compared to the same periods of
2020. Production efficiencies from stronger sales and productivity improvements were the main drivers of the
margin improvement in both the first nine months and the third quarter. Higher raw material costs had a slight
negative impact on the gross margin for the first nine months and a bit more of a negative impact in the third
quarter.
Operating costs totaled DKK 3,422 million in the first nine months and DKK 1,092 million in the third quarter of
2021. This was an increase of DKK 283 million (9%) and DKK 53 million (5%) compared to the corresponding
periods of 2020. The increase in operating costs was due to increased commercial activities, a one-off cost
following the consolidation of R&D activities in the first quarter and the inclusion of acquisitions.
• Sales and distribution costs increased by 12% and made up 12% of sales for the first nine months of
the year and were up by 19% to make up 12% of sales in the third quarter.
• Research and development costs increased by 6%, making up 13% of sales, and fell by 9% in the third
quarter to make up 12% of sales.
• Administrative costs were up by 10%, accounting for 5% of sales, and were up by 12% to make up 5%
of sales in the third quarter.
Other operating income amounted to DKK 150 million in the first nine months and DKK 10 million in the third
quarter of 2021. This was DKK 97 million and DKK 2 million more respectively than in the corresponding periods
of 2020. The DKK 97 million increase in other operating income was partly due to a realized gain from the sale
of a non-core administration building and partly due to contingent income from the divested pharma-related
royalty, both recognized in the first quarter of 2021.
Depreciation and amortization amounted to DKK 1,071 million in the first nine months and DKK 353 million in
the third quarter of 2021. This was 17% and 12% higher respectively than in the corresponding periods of 2020
and mainly due to amortization related to the PrecisionBiotics Group and the Microbiome Labs acquisitions.
EBIT amounted to DKK 3,202 million in the first nine months and DKK 1,095 million in the third quarter of 2021
for EBIT margins of 28.8% and 29.1% respectively. This was an increase of DKK 346 million, or 1.8 percentage
points, in the first nine months and an increase of DKK 201 million, or 3.0 percentage points, in the third quarter
compared to EBIT and the EBIT margins for the same periods of 2020. Higher operating costs, mainly due to the
aforementioned R&D one-off and the inclusion of acquisitions, were more than offset by the higher gross profit
and the increase in other operating income. Currencies provided a slight headwind in the first nine months and
a slight tailwind in the third quarter.
The 2021 first quarter one-offs (the contingent income from the divested pharma-related royalty, the sale of a
non-core administration building and the R&D reorganization) and the effect of the two recent Human Health
acquisitions had a roughly net neutral effect on the reported EBIT margin for the first nine months of the year.
The third-quarter EBIT margin was not impacted by any one-offs but had a negative impact from the
Microbiome Labs acquisition of roughly a half percentage point, mainly due to the M&A related depreciation
not being included in the 2020 base. The EBIT margin effect from the acquisition of Precisionbiotics Group was
annualized in the third quarter of 2021 and the effect from the Microbiome Labs acquisitions will be annualized
in the first quarter of 2022.
Net financial costs and share of losses in associates totaled DKK 49 million in the first nine months,
corresponding to a decrease in costs of DKK 92 million year on year. In the third quarter, net financial costs and
Total costs
+4%
Gross margin
58.2%
Operating costs
+9%
Depreciation and amortization
DKK 1,071 million
EBIT
DKK 3,202 million
EBIT margin
28.8%
Net financial costs and share of
losses in associates
DKK 49 million
Interim report for 9M 2021. Company announcement No. 47
8/28
share of losses in associates totaled DKK 41 million. This was an increase in costs of DKK 36 million compared to
the third quarter of last year.
Profit before tax amounted to DKK 3,153 million in the first nine months and DKK 1,054 million in the third
quarter of 2021. This was DKK 438 million (16%) and DKK 166 million (19%) respectively more than in the same
periods of 2020, primarily driven by higher operating profit and lower net financial costs in the first nine months.
The effective tax rate was 20.0% in both the first nine months and the third quarter of 2021. This was on par
compared to the same periods of 2020.
Net profit amounted to DKK 2,522 million in the first nine months and DKK 843 million in the third quarter of
2021. This was an increase of DKK 350 million (16%) and DKK 132 million (19%) respectively compared to the
same periods of 2020 due to the increase in profit before tax.
Effective tax rate
20.0%
Net profit
DKK 2,522 million
Interim report for 9M 2021. Company announcement No. 47
9/28
Cash flows and balance sheet
Cash flow from operating activities amounted to DKK 3,367 million in the first nine months and DKK 1,110
million in the third quarter of 2021. This was an increase of DKK 58 million and DKK 216 million respectively
compared to the same periods of 2020 and mainly driven by the higher net profit, including an improved
earnings quality, and despite an increase in net working capital.
Net investments excluding acquisitions totaled DKK 638 million in the first nine months of 2021, which was DKK
45 million higher than in the same period of 2020. In the third quarter, net investments amounted to DKK 227
million, which was roughly on par with the third quarter of last year.
Free cash flow before acquisitions amounted to DKK 2,729 million in the first nine months and DKK 883 million
in the third quarter of 2021. This was an increase of DKK 13 million and DKK 218 million compared to the same
periods of 2020. The changes in the first nine months and in the third quarter compared to the same periods
last year were mainly attributable to changes in cash flow from operations.
Shareholders’ equity including minority interests was DKK 11,578 million on September 30, 2021, corresponding
to an equity ratio of 53.0%. This was an increase of DKK 767 million, corresponding to a decrease of 0.7
percentage point compared to the shareholders’ equity of DKK 10,811 million and the 53.7% equity ratio
reported at September 30, 2020.
Net interest-bearing debt (NIBD) and the NIBD-to-EBITDA ratio were DKK 4,707 million and 0.8x respectively at
September 30, 2021. This was an increase of DKK 105 million and a decrease of 0.1x respectively compared to
the net interest-bearing debt and the NIBD-to-EBITDA ratio at September 30, 2020.
Return on invested capital (ROIC) including goodwill was 22.1% in the first nine months and 21.4% in the third
quarter of 2021. This was 2.9 and 2.5 percentage points higher respectively than in the same periods of 2020.
The improvement in ROIC, both in the first nine months and in the third quarter, was due to the higher net
operating profit after tax which more than offset an increase in average invested capital following the
PrecisionBiotics Group and Microbiome Labs acquisitions.
The holding of treasury stock was 5,059,286 B shares at September 30, 2021, equivalent to 1.8% of the common
stock.
Operating cash flow
DKK 3,367 million
Net investments excl. acq.
DKK 638 million
Free cash flow before acquisitions
DKK 2,729 million
Equity ratio
53.0%
NIBD/EBITDA
0.8x
ROIC
22.1%
Treasury stock
1.8%
Interim report for 9M 2021. Company announcement No. 47
10/28
2021 outlook
2021 outlook
October 26*
2021 outlook
August 12
2021 outlook
February 2
Sales performance, organic
%
5 to 6
4 to 6
2 to 6
EBIT margin
%
~27
~26
25 to 26
ROIC (including goodwill)
%
20 to 21
19 to 20
~19
Free cash flow before acquisitions
DKKbn
2.8 to 3.2
2.5 to 2.9
2.7 to 3.1
For modeling purposes:
Effective tax rate
%
~20
~20
~20
Net financial costs
DKKm
~100
~75
~50
Net investments
DKKbn
1.3 to 1.5
1.3 to 1.5
1.0 to 1.2
Stock buyback program
DKKbn
completed at 1.5
up to 1.5
up to 1.5
*Assumes constant currencies from the time of this announcement and for the remainder of the year
Sales outlook
The full-year sales outlook is narrowed to the upper end of the former range following a strong first-nine-month
performance and including the assumptions for the fourth quarter. The updated outlook is for organic sales to
grow by 5% to 6% in 2021. Primarily Food, Beverages & Human Health and Grain & Tech Processing have
performed better than expected, and Bioenergy is now indicated to end the year at the upper end of the
previous range. Household Care saw a somewhat softer performance relative to expectations in the third
quarter following weakness in the European laundry market, which is expected to carry over into the fourth
quarter. The full-year indication for Agriculture, Animal Health & Nutrition is maintained. Sales growth in
reported DKK, including currency and M&A, are expected to be roughly on par with the organic sales growth.
The full-year outlook does not consider another extended global lockdown situation.
Household Care (organic 0% in 9M 2021) organic sales performance will benefit from market penetration,
particularly in emerging markets, and the continued rollout of the Freshness technology. The broad-market
version of the Freshness technology was successfully launched in the third quarter, marking an important
milestone, and is expected to become a significant growth contributor in future years. As demand in the
European laundry market looks softer than previously expected, including some specific private-label customers
experiencing difficulties, Household Care is now expected to close the year at around flat performance following
5% organic sales growth in 2020.
Food, Beverages & Human Health (organic 15% in 9M 2021) organic sales growth is expected to be broad based
across subareas. Innovation, emerging market penetration, increasing consumer dietary health awareness and
plant-based proteins are the main drivers of growth in Food. Beverages is expected to gradually recover from
last year’s COVID-19 impacted performance and Human Health is estimated to grow organically at strong
double-digit rates. Following a better underlying momentum with high consumption levels and less-than-
expected destocking, indications are for Food, Beverages & Human Health to grow by low double-digits
organically in 2021.
Bioenergy (organic 12% in 9M 2021) organic sales growth is expected to be driven by a gradual recovery of U.S.
ethanol production as COVID-19 restrictions are lifted, continued capacity expansion of corn-based ethanol
Interim report for 9M 2021. Company announcement No. 47
11/28
production in Latin America, and market penetration supported by innovation. Biodiesel is expected to do well
and grow by double digits organically, although from a relatively low absolute level. The full-year indication for
Bioenergy is expected at high single-digit organic sales growth.
Grain & Tech Processing (organic 12% in 9M 2021) organic sales growth is expected to come from a broad base
across most subareas in both Grain and Tech Processing. Growth in Grain will be driven by innovation and
increased market penetration supported by local presence, whereas a gradual recovery of the global textile
industry will be a key contributor to growth in Tech Processing. Following an improved underlying momentum
and less-than-expected destocking, Grain & Tech Processing is now indicated to grow organically by high single-
digits in 2021.
Agriculture, Animal Health & Nutrition (organic -3% in 9M 2021) organic sales growth will be driven by
innovation in Animal Health & Nutrition. The agriculture business is expected to deliver solid underlying double-
digit organic sales growth in 2021 when adjusted for the DKK ~60 million one-off in the second quarter of 2020,
with continued expansion across crops and regions. The full-year indication for Agriculture, Animal Health &
Nutrition is maintained at low single-digit organic growth.
Profit outlook
For 2021, Novozymes expects a reported EBIT margin of around 27% (2020: 26.1%). The EBIT margin outlook
includes a slightly negative year on year impact from currencies and close to a ~1 percentage point negative
impact from M&A. The M&A-related effects are attributable to amortization and integration costs. Supportive
margin contribution from sales growth and productivity improvements are expected to be partly offset by
continued re-investments as well as higher freight costs and raw material prices, which at current levels are
expected to have a negative impact over the coming quarters.
The outlook for the return on invested capital (ROIC) including goodwill is expected at 20% to 21% (2020:
18.9%).
The 2021 outlook for free cash flow (FCF) before acquisitions is raised and is now expected to be DKK 2.8-3.2
billion (2020: DKK 3.4 billion) following improved operating results.
For modeling purposes, the following is provided:
The effective tax rate is expected at ~20% for 2021 (2020: 19.7%).
Net financial costs are now expected to be DKK ~100 million (2020: DKK 127 million), with DKK ~150 million
relating to interest expenses, banking fees, lease and financial costs related to acquisition earnouts. The DKK
~150 million is partly offset by a positive effect from USD/DKK currency hedging.
Net investments during 2021 will amount to DKK 1.3-1.5 billion (2020: DKK 0.9 billion) reflecting maintenance,
optimization and expansion investments as well as DKK 300 million impacting 2021 as part of the DKK 2 billion
investment in the new production line for Alternative Protein Solutions in Blair, Nebraska, US.
The stock buyback program of up to DKK 1.5 billion was initiated effective February 8, 2021 and completed on
August 27, 2021.
EBIT margin
~27%
ROIC, incl. goodwill
20% to 21%
FCF before acquisitions
DKK 2.8 to 3.2 billion
Effective tax rate
~20%
Net financial costs
DKK ~100 million
Net investments
DKK 1.3 to 1.5 billion
Stock buyback program
DKK 1.5 billion completed
Interim report for 9M 2021. Company announcement No. 47
12/28
Sustainability outlook
In 2021, we will continue to invest in developing solutions that support better lives in a growing world as well
as progress on our 2022 targets on climate, water, production and consumption. We will expand the reach and
benefits of our solutions and expect to deliver an even greater impact by replacing chemicals and enabling CO
2
reductions. We will further develop our employee programs focused on learning, well-being and improving their
engagement towards our sustainability commitment.
2022 targets
World
Save CO
2
emissions by enabling low carbon fuels in the transport sector
60 million tons of CO
2
Reach people by providing laundry solutions that replace chemicals
>4 billion people
Gain food by improving efficiency from farm to table
500,000 tons of food
Operations
Reduce absolute CO
2
emissions from operations
1
40%
Develop context-based water management programs
100% of sites
2
Develop zero waste programs
100% of sites
2
Manage biomass in circular systems
100%
Develop circular management plans for key packaging materials
100%
Employees
Enable learning
3
80
Nurture diversity
4
86
Occupational injuries
5
≤ 1.5
Pledge employee time to local outreach
6
~ 1% of time
Excite employees
3
81
1
Compared to 2018 baseline
2
The target does not include sites with activities considered not to have a significant environmental impact, e.g sales offices, R&D labs, etc
3
Measured by score to relevant questions in annual survey
4
Index calculated based on gender and national representation at various professional levels
5
Defined as the three-year rolling average of lost time injuries per million working hours
6
Qualitative reporting only
Interim report for 9M 2021. Company announcement No. 47
13/28
Currency exposure
Sales by currency, 9M 2021
Other things being equal, a 5% movement in USD/DKK is expected to have an annual positive/negative impact
on EBIT of around DKK 130-160 million, and a 5% movement in EUR/DKK is expected to have an annual
positive/negative impact on EBIT of DKK ~200 million.
Hedging of net currency exposure
2021
2022
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
USD
100% hedged via forward contracts
at average USD/DKK 6.38
63% hedged via forward contracts
at average USD/DKK 6.18
The expected USD currency exposure for 2021 is 100% hedged at an average of USD/DKK 6.38. The 2021 outlook
is based on expected exchange rates for the company's key currencies remaining at the closing rates on October
25 for the full year.
DKK
EUR
USD
BRL
CNY
Average exchange rate 9M 2021
744
622
117
96
Average exchange rate 9M 2020
746
663
133
95
Average exchange rate 9M 2021 compared to 9M 2020
0%
-7%
-14%
1%
Rate on October 25, 2021
744
641
114
100
Estimated average exchange rate 2021
*
744
627
116
97
Estimated average exchange rate 2021 compared to 2020
0%
-4%
-10%
3%
* Estimated average exchange rate on October 25, 2021
~36%
~34%
~9%
~7%
~14%
EUR
USD
CNY
DKK
Others
Interim report for 9M 2021. Company announcement No. 47
14/28
Accounting policies
The interim report for the first nine months of 2021 has been prepared in accordance with IAS 34 and additional
Danish regulations for the presentation of quarterly interim reports by listed companies. The interim report for
the first nine months of 2021 follows the same accounting policies as the annual report for 2020, except for all
new, amended or revised accounting standards and interpretations (IFRSs) endorsed by the EU effective for the
accounting period beginning on January 1, 2021. These IFRSs have not had any impact on the Group’s interim
report.
Forward-looking statements
This company announcement and its related comments contain forward-looking statements, including
statements about future events, future financial performance, plans, strategies and expectations. Forward-
looking statements are associated with words such as, but not limited to, "believe," "anticipate," "expect,"
"estimate," "intend," "plan," "project," "could," "may," "might" and other words of similar meaning. Forward-
looking statements are by their very nature associated with risks and uncertainties that may cause actual results
to differ materially from expectations, both positively and negatively. The risks and uncertainties may, among
other things, include unexpected developments in i) the ability to develop and market new products; ii) the
demand for Novozymes' products, market-driven price decreases, industry consolidation, and launches of
competing products or disruptive technologies in Novozymes' core business areas; iii) the ability to protect and
enforce the company's intellectual property rights; iv) significant litigation or breaches of contract; v) the
materialization of the company's market-expanding growth platforms, notably the development of microbial
solutions for broad-acre crops; vi) political conditions, such as acceptance of enzymes produced by genetically
modified organisms; vii) global economic and capital market conditions, including, but not limited to, currency
exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and inflation; viii)
significant price decreases for inputs and materials that compete with Novozymes' biological solutions. The
company undertakes no obligation to update any forward-looking statements as a result of future
developments or new information.
Contact information
Investor Relations
Tobias Bjorklund
+45 3077 8682
tobb@novozymes.com
Ulrik Wu Svare
Parental leave
Parental leave
Carl Ahlgren (U.S.)
+1 919 702 6144
cxal@novozymes.com
Media Relations
Lina Danstrup
+45 3077 0552
lind@novozymes.com
Interim report for 9M 2021. Company announcement No. 47
15/28
Statement of the Board of Directors and the Executive
Management
Bagsværd, October 26, 2021
EXECUTIVE MANAGEMENT
Ester Baiget
President & CEO
Lars Green
CFO
BOARD OF DIRECTORS
Jørgen Buhl Rasmussen
Chair
Cornelis (Cees) de Jong
Vice Chair
Anne Breum
Heine Dalsgaard
Sharon James
Anders Hentze Knudsen
Kasim Kutay
Preben Nielsen
Kim Stratton
Mathias Uhlén
Jens Øbro
Interim report for 9M 2021. Company announcement No. 47
16/28
Appendices
Appendix 1 Main items and key figures 17
Key figures 17
Income statement 18
Statement of comprehensive income 19
Appendix 2 Distribution of revenue 20
Business areas 20
Geography 20
Appendix 3 Statement of cash flows 22
Statement of cash flows 22
Appendix 4 Balance sheet and Statement of shareholders' equity 23
Balance sheet, Assets 23
Balance sheet, Liabilities 24
Statement of shareholders' equity 25
Investment in new production line 26
Appendix 5 Miscellaneous 27
Public product launches in 2021 27
Company announcements and news in the 2021 financial year 28
Interim report for 9M 2021. Company announcement No. 47
17/28
Appendix 1 Main items and key figures
Key figures
DKK million 9M 2021 9M 2020 % change Q3 2021 Q3 2020 % change
Revenue 11,117 10,566 5% 3,761 3,431 10%
Gross profit 6,474 5,942 9% 2,177 1,925 13%
Gross margin 58.2% 56.2% 57.9% 56.1%
EBITDA 4,273 3,775 13% 1,448 1,209 20%
EBITDA margin 38.4% 35.7% 38.5% 35.2%
Operating profit / EBIT 3,202 2,856 12% 1,095 894 22%
EBIT margin 28.8% 27.0% 29.1% 26.1%
Share of result in associates (2) (2) - (1)
Net financials (47) (139) (41) (5)
Profit before tax 3,153 2,715 16% 1,054 888 19%
Tax (631) (543) 16% (211) (177) 19%
Net profit 2,522 2,172 16% 843 711 19%
Earnings per DKK 2 share 9.06 7.73 17% 3.04 2.54 19%
Earnings per DKK 2 share (diluted) 8.99 7.69 17% 3.01 2.53 19%
Net investments excl. acq. 638 593 8% 227 229 (1)%
Free cash flow before net acq. and
purchase of financial assets
2,729 2,716 0% 883 665 33%
Return on invested capital (ROIC)
incl. goodwill
22.1% 19.2%
Net interest-bearing debt 4,707 4,602
Equity ratio 53.0% 53.7%
Return on equity 29.5% 26.0%
Debt-to-equity 40.7% 42.6%
NIBD / EBITDA 0.8 0.9
Number of employees 6,369 6,180
Novozymes' stock
Sep. 30,
2021
Sep. 30,
2020
Common stock (million)
282.0 285.0
Net worth per share (DKK)
41.01 37.89
Denomination of share (DKK)
2.00 2.00
Nominal value of common stock (DKK million)
564.0 570.0
Treasury stock (million)
5.1 5.9
Interim report for 9M 2021. Company announcement No. 47
18/28
Income statement
DKK million 9M 2021 9M 2020 Q3 2021 Q3 2020
Revenue 11,117 10,566 3,761 3,431
Cost of goods sold (4,643 ) (4,624 ) (1,584) (1,506)
Gross profit 6,474 5,942 2,177 1,925
Sales and distribution costs (1,327 ) (1,187 ) (456) (383)
Research and development costs (1,497 ) (1,407 ) (435) (477)
Administrative costs (598 ) (545 ) (201) (179)
Other operating income, net 150 53 10 8
Operating profit / EBIT 3,202 2,856 1,095 894
Share of result in associates (2 ) (2 ) - (1)
Net financials (47 ) (139 ) (41) (5)
Profit before tax 3,153 2,715 1,054 888
Tax (631 ) (543 ) (211) (177)
Net profit 2,522 2,172 843 711
Attributable to
Shareholders in Novozymes A/S 2,521 2,171 842 711
Non-controlling interests 1 1 1 -
Specification of net financials
Foreign exchange gain/(loss), net 50 (69 ) (11) 20
Interest income/(costs) (31 ) (40 ) (9) (15)
Other financial items (66 ) (30 ) (21) (10)
Net financials (47 ) (139 ) (41) (5)
Earnings per DKK 2 share 9.06 7.73 3.04 2.54
Average no. of A/B shares outstanding (million) 278.2 280.8 277.1 279.5
Earnings per DKK 2 share (diluted) 8.99 7.69 3.01 2.53
Average no. of A/B shares, diluted (million) 280.4 282.4 279.8 281.4
Interim report for 9M 2021. Company announcement No. 47
19/28
Statement of comprehensive income
DKK million 9M 2021 9M 2020 Q3 2021 Q3 2020
Net profit
Currency translation of subsidiaries and non-controlling
interests
Currency translation adjustments
Fair value adjustments
(136 ) 58 (57) 81
Tax on fair value adjustments
Cash flow hedges reclassified to financial costs (63 ) 27 7 (19)
Tax on reclassified fair value adjustments
Cash flow hedges
(155 ) 66 (39) 48
Other comprehensive income
Comprehensive income
Attributable to
Shareholders in Novozymes A/S 2,863 1,729 1,006 450
Non-controlling interests 2 - 1 (1)
Interim report for 9M 2021. Company announcement No. 47
20/28
Appendix 2 Distribution of revenue
Business areas
Geography
2021 2020 % change % currency % M&A % organic
DKK million 9M 9M impact impact growth
Consumer Biosolutions
Household Care
3.613 3.709 (3) (3) 0 0
Food, Beverages & Human Health
2.613 2.101 24 (3) 12 15
Agriculture & Industrial Biosolutions
Bioenergy
1.914 1.829 5 (7) 0 12
Grain & Tech Processing
1.657 1.520 9 (3) 0 12
Agriculture, Animal Health & Nutrition
1.320 1.407 (6) (3) 0 (3)
Sales 11.117 10.566 5 (4) 3 6
2021 2020 % change % currency % M&A % organic
DKK million Q3 Q3 impact impact growth
Consumer Biosolutions
Household Care
1.247 1.211 3 0 0 3
Food, Beverages & Human Health
870 684 27 0 11 16
Agriculture & Industrial Biosolutions
Bioenergy
675 647 4 (1) 0 5
Grain & Tech Processing
539 515 5 1 0 4
Agriculture, Animal Health & Nutrition
430 374 15 (1) 0 16
Sales 3.761 3.431 10 0 3 7
% change
DKK million Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q3/Q3
Consumer Biosolutions
Household Care
1.247 1.125 1.241 1.173 1.211 1.227 1.271 3
Food, Beverages & Human Health
870 878 865 666 684 680 737 27
Agriculture & Industrial Biosolutions
Bioenergy
675 651 588 693 647 463 719 4
Grain & Tech Processing
539 529 589 487 515 467 538 5
Agriculture, Animal Health & Nutrition
430 397 493 427 374 512 521 15
Sales 3.761 3.580 3.776 3.446 3.431 3.349 3.786 10
2020
2021
2021 2020
% change % currency % M&A % organic
DKK million 9M 9M impact impact growth
Europe, Middle East & Africa 4.309 4.204 2 0 0 2
North America 3.373 3.335 1 (6) 5 2
Asia Pacific 2.247 2.047 10 (2) 0 12
Latin America 1.188 980 21 (10) 0 31
Sales 11.117 10.566 5 (4) 3 6
Developed markets 7.017 7.021 0 (3) 3 0
Emerging markets 4.100 3.545 16 (4) 0 20
Sales 11.117 10.566 5 (4) 3 6
2021 2020 % change % currency % M&A % organic
DKK million Q3 Q3 impact impact growth
Europe, Middle East & Africa 1.443 1.403 3 0 0 3
North America 1.131 1.060 7 (1) 7 1
Asia Pacific 728 642 13 2 0 11
Latin America 459 326 41 0 0 41
Sales 3.761 3.431 10 0 3 7
Developed markets 2.311 2.283 1 (1) 3 (1)
Emerging markets 1.450 1.148 26 1 0 25
Sales 3.761 3.431 10 0 3 7
Interim report for 9M 2021. Company announcement No. 47
21/28
% change
DKK million Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q3/Q3
Europe, Middle East & Africa 1.443 1.409 1.457 1.332 1.403 1.347 1.454 3
North America 1.131 1.076 1.166 1.106 1.060 1.011 1.264 7
Asia Pacific 728 733 786 708 642 697 708 13
Latin America 459 362 367 300 326 294 360 41
Sales 3.761 3.580 3.776 3.446 3.431 3.349 3.786 10
Developed markets 2.311 2.289 2.417 2.280 2.283 2.201 2.537 1
Emerging markets 1.450 1.291 1.359 1.166 1.148 1.148 1.249 26
Sales 3.761 3.580 3.776 3.446 3.431 3.349 3.786 10
2020
2021
Interim report for 9M 2021. Company announcement No. 47
22/28
Appendix 3 Statement of cash flows
Statement of cash flows
DKK million 9M 2021 9M 2020 Q3 2021 Q3 2020
Net profit
Reversals of non-cash items
Tax paid
(285 ) (405 ) (65) (90)
Interest received
Interest paid
(39 ) (48 ) (14) (20)
Cash flow before change in working capital
Change in working capital
(Increase)/decrease in receivables and contract assets
(437 ) 245 (280) (22)
(Increase)/decrease in inventories
(445 ) 33 (148) 70
Increase/(decrease) in payables, deferred income and
contract liabilities
Currency translation adjustments
(9 ) (12 ) (14) (2)
Cash flow from operating activities
Investments
Purchase of intangible assets
(107 ) (94 ) (34) (32)
Sale of property, plant and equipment
Purchase of property, plant and equipment
(534 ) (502 ) (194) (199)
(638 ) (593 ) (227) (229)
Business acquisitions, divestments and purchase of financial
assets
(761 ) (585 ) - (1)
Free cash flow
Financing
Borrowings
Repayment of borrowings
(1,196 ) (298 ) (663) (231)
Overdraft facilities, net
Repayment of lease liabilities
(77 ) (86 ) (25) (27)
Shareholders:
Purchase of treasury stock
(1,500 ) (1,500 ) (368) (573)
Sale of treasury stock
Dividend paid
(1,466 ) (1,483 ) - -
Cash flow from financing activities
(2,278 ) (1,956 ) (988) (817)
Net cash flow
(310 ) 175 (105) (153)
Unrealized gain/(loss) on currencies and financial assets,
included in cash and cash equivalents
(8 ) (30 )
(1)
(15)
Change in cash and cash equivalents, net
(318 ) 145 (106) (168)
Cash and cash equivalents - Beginning of period
Cash and cash equivalents at September 30
Undrawn committed credit facilities at September 30, 2021 were DKK 4,489 million.
Cash flow from investing activities before acquisitions,
divestments and purchase of financial assets
Free cash flow before acquisitions, divestments and
purchase of financial assets
Interim report for 9M 2021. Company announcement No. 47
23/28
Appendix 4 Balance sheet and Statement of shareholders' equity
Balance sheet, Assets
DKK million
Sep. 30,
2021
Sep. 30,
2020
Dec. 31,
2020
Completed IT development projects 173 177 205
Acquired patents, licenses and know-how
Goodwill
IT development projects in progress
Intangible assets 3,544 2,616 2,554
Land and buildings
Plant and machinery
Other equipment 1,038 922 941
Assets under construction and prepayments
Property, plant and equipment 9,755 9,717 9,612
Deferred tax assets 1,248 1,127 1,339
Other financial assets (non-interest-bearing) 29 21 21
Investment in associate 31 35 33
Other receivables
Non-current assets 14,637 13,545 13,599
Raw materials and consumables 398 376 353
Goods in progress 970 787 720
Finished goods
Inventories 2,860 2,528 2,361
Trade receivables 2,832 2,687 2,549
Contract assets 13 21 6
Tax receivables 88 112 460
Other receivables
Receivables 3,413 3,098 3,227
Other financial assets (non-interest-bearing) 41 78 119
Cash and cash equivalents 863 856 1,181
Assets held for sale
Current assets 7,189 6,582 6,911
Assets 21,826 20,127 20,510
Interim report for 9M 2021. Company announcement No. 47
24/28
Balance sheet, Liabilities
DKK million
Sep. 30,
2021
Sep. 30,
2020
Dec. 31,
2020
Common stock 564 570 570
Currency translation adjustments (230 ) (451 ) (727 )
Cash flow hedges (28 ) 85 127
Retained earnings
Equity attributable to shareholders in Novozymes A/S
Non-controlling interests
Shareholders' equity 11,578 10,811 11,244
Deferred tax liabilities 944 882 1,204
Provisions 106 106 115
Contingent consideration 587 146 146
Deferred income 97 - -
Other financial liabilities (interest-bearing) 3,712 3,485 3,245
Other financial liabilities (non-interest-bearing) 12 11 9
Non-current lease liabilities
Non-current liabilities 5,835 5,033 5,105
Other financial liabilities (interest-bearing) 1,325 1,431 1,285
Other financial liabilities (non-interest-bearing) 92 23 24
Lease liabilities 156 139 136
Provisions 20 101 90
Trade payables 1,162 992 1,100
Contract liabilities 138 64 67
Deferred income 33 25 22
Tax payables 318 336 336
Other payables
Current liabilities 4,413 4,283 4,161
Liabilities 10,248 9,316 9,266
Liabilities and shareholders' equity 21,826 20,127 20,510
Interim report for 9M 2021. Company announcement No. 47
25/28
Statement of shareholders' equity
DKK million
Common
stock
Currency
translation
adjustments
Cash flow hedges
Retained
earnings
Total
Non-
controlling
interests
Total
Shareholders' equity at January 1, 2021
Net profit for the period
Other comprehensive income for the period
Total comprehensive income for the period
Purchase of treasury stock
(1,500 ) (1,500 ) (1,500 )
Sale of treasury stock
Write-down of common stock
(6 ) 6 - -
Dividend
(1,465 ) (1,465 ) (1 ) (1,466 )
Stock-based payment
Tax related to equity items
Changes in shareholders' equity
(6 ) 497 (155 ) (3 ) 333 1 334
Shareholders' equity at September 30, 2021
Shareholders' equity at January 1, 2020
Net profit for the period
Other comprehensive income for the period
(508 ) 66 (442 ) (1 ) (443 )
Total comprehensive income for the period
(508 ) 66 2,171 1,729 - 1,729
Purchase of treasury stock
(1,500 ) (1,500 ) (1,500 )
Sale of treasury stock
Write-down of common stock
(12 ) 12 - -
Dividend
(1,482 ) (1,482 ) (1 ) (1,483 )
Stock-based payment
Tax related to equity items
Changes in shareholders' equity
(12 ) (508 ) 66 (214 ) (668 ) (1 ) (669 )
Shareholders' equity at September 30, 2020
Attributable to shareholders in Novozymes A/S
Interim report for 9M 2021. Company announcement No. 47
26/28
Investment in new production line
Investment in new state of the art production line in Blair, Nebraska
Novozymes is committed to establishing a new production line at its US site in Blair, Nebraska. The
investment follows an agreement by Novozymes to enter into a long-term contract with an anchor
customer and key player in the plant-based industry and delivers on Novozymes’ stated purpose of
creating better lives in a growing world, by feeding the world sustainably.
The capital investment of roughly DKK 2 billion will span over the period 2021-2023, starting in the
second half of 2021 and with expected completion by the end of 2023. Most of the investment
activities are planned for 2022 and 2023, and DKK 16 million had been incurred at September 30,
2021.
The current contractual obligations to third parties relating to property, plant and equipment
amount to DKK 1.2 billion.
Interim report for 9M 2021. Company announcement No. 47
27/28
Appendix 5 Miscellaneous
Public product launches in 2021
Product
Description
Sustainability benefit*
ProAct 360™
ProAct 360™ is a protease solution helping
poultry producers to achieve sustainable and
profitable production by improving amino
acid digestibility.
ProAct 360™ reduces nitrogen emissions into
the environment via manure by improving the
digestibility of proteins in animal feed.
Innova® Element
Innova® Element targets ethanol plants
seeking the highest level of starch and
glucose conversion for their fermentation
process.
Higher yields reduce the total greenhouse
gas emissions from the ethanol, thereby
increasing the climate benefit from gasoline
displacement.
Fiberex® F2.5
Fiberex® F2.5 is a combination of
hemicellulases and cellulases designed to
efficiently extract and convert the cellulose
found in the corn kernel.
Fiberex F2.5 further improves the feasibility
of turning corn kernel fiber, a low-value feed
component, into a high-value fuel with a low
carbon intensity.
Alflorex® Immune
Alflorex Immune helps support and
maintain a normal immune function. It is
specifically designed to combat viral
infections.
Alflorex Immune is a food supplement that
helps people with an irritable bowel against
bloating, diarrhea and abdominal pain. It is
based on a bacterial culture.
Pristine®
Pristine® is a phosphodiesterase enzyme
(PDE) that breaks down invisible layers of
body grime. Clothes get hygienically clean,
and are less prone to yellowing,
decolorization, and forming that lingering
odor.
By removing and preventing odor and
dinginess over time, consumers are
motivated to keep their clothing and home
textiles for longer. With an extended lifetime
of clothes, fewer textiles need to be
produced and disposed of to benefit the
environment. Pristine® acts at low
temperatures enabling energy savings during
wash. It also provides a biological alternative
to chemical ingredients used in detergents
today.
Optimize FXC
Optimize FXC liquid inoculant combines
Bradyrhizobia and fortified LCO promoter
technology to increase nitrogen fixation,
accessibility to soil nutrients and water
absorption in soybean plants.
Optimize FXC gives higher soybean yields
with the same inputs and thereby reduces
soybeans' environmental footprint.
BioniQ
BioniQ is a family of inoculants that
enhance nitrate, phosphate, and potassium
availability. The products in the BioniQ
family work on corn, sorghum, canola, all
cereals crops, mustard, barley, and pulse
crops.
Producing more from the same inputs
reduces the environmental impact per kg of
output.
Taegro 2
Taegro 2 is an OMRI-certified, broad-
spectrum, foliar fungicide for fruit and
vegetable crops that controls against
powdery mildew and botrytis, among
others, to maximize marketable yields.
Taegro2 is safe for natural pollinators and
can be used right before harvest without the
risk of residues in the crops.
* The sustainability benefits are based on quantitative and/or qualitative evaluations where applicable.
Interim report for 9M 2021. Company announcement No. 47
28/28
Company announcements and news in the 2021 financial year
(Excluding Management's trading in the Novozymes stock, major shareholder announcements and stock buyback status)
February 2, 2021
Group financial statement for 2020
February 2, 2021
Election of employee representatives to the Board of Directors of Novozymes A/S
February 8, 2021
Initiation of stock buyback
March 11, 2021
Novozymes A/S Annual Shareholders' Meeting 2021
April 12, 2021
Reduction of share capital
April 27, 2021
Interim report for Q1 2021
August 12, 2021
Novozymes reaches a strategic milestone in the implementation of its strategy with a significant
entry into Advanced Protein Solutions
August 12, 2021
Interim report for the first half of 2021
October 26, 2021
Interim report for the first nine months of 2021